144 related articles for article (PubMed ID: 38918202)
21. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
[TBL] [Abstract][Full Text] [Related]
22. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Peffault de Latour R; Rottinghaus ST; Röth A; Risitano AM; Weitz IC; Hillmen P; Maciejewski JP; Szer J; Lee JW; Kulasekararaj AG; Volles L; Damokosh AI; Ortiz S; Shafner L; Liu P; Hill A; Schrezenmeier H
Haematologica; 2021 Jan; 106(1):230-237. PubMed ID: 31949012
[TBL] [Abstract][Full Text] [Related]
23. Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria.
Yoo JJ; Chonat S
Expert Rev Hematol; 2022 May; 15(5):385-392. PubMed ID: 35502699
[TBL] [Abstract][Full Text] [Related]
24. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
25. Non-capsulated
Galli N; Pettine L; Panigada M; Daprai L; Suriano G; Grancini A; Barcellini W; Fattizzo B
Front Immunol; 2023; 14():1269325. PubMed ID: 37854608
[TBL] [Abstract][Full Text] [Related]
26. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria.
Schwartz CE; Stark RB; Borowiec K; Nolte S; Myren KJ
Orphanet J Rare Dis; 2021 Sep; 16(1):389. PubMed ID: 34526067
[TBL] [Abstract][Full Text] [Related]
27. Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.
Wong SA; Dalal BI; Leitch HA
Curr Oncol; 2018 Oct; 25(5):e391-e397. PubMed ID: 30464689
[TBL] [Abstract][Full Text] [Related]
28. Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.
Kelly RJ; Holt M; Vidler J; Arnold LM; Large J; Forrest B; Barnfield C; Pike A; Griffin M; Munir T; Muus P; Nagumantry SK; Varghese A; Davies JR; Trikha R; Kulasekararaj AG; Mitchell L; Gandhi S
Blood; 2024 Mar; 143(12):1157-1166. PubMed ID: 38142401
[TBL] [Abstract][Full Text] [Related]
29. Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.
O'Connell T; Buessing M; Johnson S; Tu L; Thomas SK; Tomazos I
Pharmacoeconomics; 2020 Sep; 38(9):981-994. PubMed ID: 32519233
[TBL] [Abstract][Full Text] [Related]
30. Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network.
Fishman J; Kuranz S; Yeh MM; Brzozowski K; Chen H
Hematol Rep; 2023 Apr; 15(2):266-282. PubMed ID: 37092521
[TBL] [Abstract][Full Text] [Related]
31. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Schrezenmeier H; Kulasekararaj A; Mitchell L; de Latour RP; Devos T; Okamoto S; Wells R; Popoff E; Cheung A; Wang A; Tomazos I; Patel Y; Lee JW
Ann Hematol; 2024 Jan; 103(1):5-15. PubMed ID: 37804344
[TBL] [Abstract][Full Text] [Related]
32. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
Risitano AM; Kulasekararaj AG; Lee JW; Maciejewski JP; Notaro R; Brodsky R; Huang M; Geffner M; Browett P
Haematologica; 2021 Dec; 106(12):3188-3197. PubMed ID: 33121236
[TBL] [Abstract][Full Text] [Related]
33. [COVID-19 development during the treatment of paroxysmal nocturnal hemoglobinuria].
Shino M; Iizuka H; Fukushima H; Takeyasu S; Kamoda Y; Kida M; Ichikawa M; Anazawa R; Sakurai T; Usuki K
Rinsho Ketsueki; 2023; 64(3):224-229. PubMed ID: 37019678
[TBL] [Abstract][Full Text] [Related]
34. Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Gurnari C; Nautiyal I; Pagliuca S
Ther Clin Risk Manag; 2021; 17():1343-1351. PubMed ID: 34934322
[TBL] [Abstract][Full Text] [Related]
35. COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.
Shikdar S; Borogovac A; Mohamad E; Khawandanah M
Thromb J; 2021 Oct; 19(1):75. PubMed ID: 34674707
[TBL] [Abstract][Full Text] [Related]
36. Breakthrough Hemolysis Associated With COVID-19 Vaccination and Active COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report.
Boshkos MC; Fives KR; Phrathep DD; Healey KD; Patel M
Cureus; 2023 Mar; 15(3):e36240. PubMed ID: 37065335
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands.
Quist SW; Postma AJ; Myrén KJ; de Jong LA; Postma MJ
Eur J Health Econ; 2023 Dec; 24(9):1455-1472. PubMed ID: 36633725
[TBL] [Abstract][Full Text] [Related]
38. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.
Schrezenmeier H; Kulasekararaj A; Mitchell L; Sicre de Fontbrune F; Devos T; Okamoto S; Wells R; Rottinghaus ST; Liu P; Ortiz S; Lee JW; Socié G
Ther Adv Hematol; 2020; 11():2040620720966137. PubMed ID: 33178408
[TBL] [Abstract][Full Text] [Related]
39. [Novel anti-complement therapeutics for hemolytic anemia].
Nishimura JI
Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
[TBL] [Abstract][Full Text] [Related]
40. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
